Today’s answer,

tomorrow’s kidney health.

Our 3-part, proprietary methodology – bioprognosisTM for kidney health – predicts risk and outcomes to promote and preserve kidney health.

With one simple blood test, clinicians receive their patients’ custom risk scores with actionable, guideline-recommended treatment steps.

KidneyIntelX Has Received Breakthrough Device Designation from the FDA for Chronic Kidney Disease Prognosis

1

Proprietary biomarkers

Biological factors that are clinically proven – in multiple studies – to be most prognostic for kidney disease (TNFR1, TNFR2, KIM-1).

2

Select clinical features

7 select data points from a patient’s health record (eGFR, UACR, serum calcium, HbA1c, systolic BP, platelets, AST) that are indicative of kidney/other key organ health or dysfunction.

3

Validated algorithm

Machine learning combines these diverse and proprietary data inputs to maximize their value through a patient risk score.

4

Yields a clear and actionable test report:

Risk score + guideline-recommended clinical pathway

Low
Intermediate
High
Request a Meeting
Order Test
About Test
See Evidence
Patient Insurance & Billing
KidneyIntelX is the only early-stage risk assessment test

KidneyIntelX is the only

early-stage risk assessment test

for patients in stages 1-3b.

KidneyIntelX is the only bioprognostic methodology and the only option for risk assessment in adults with type 2 diabetes and with chronic kidney disease stages 1-3b.

KidneyIntelX demonstrated to be a 3X better predictor of risk vs traditional kidney function measures (eGFR and UACR).

References:
1.Data from Validation Study in Subgroup with UACR available Chan L, et al. Diabetologia 2021
2.Data from CANVAS analyses; Lam D, et al. Am J Nephrology 2021

KidneyIntelX begins at the

right starting point.

Only by starting at the earliest stages of diagnosed diabetic kidney disease – and by leveraging the only test proven to identify those select adult patients with type 2 diabetes and chronic kidney disease who are at higher to lower risk for rapid progressive decline in kidney function – will clinicians and patients reap the greatest benefits from the rest of the treatment plan.

Prognosis, not diagnosis.

KidneyIntelX graphic

Current kidney function measurements – estimated GFR and UACR – are meant to diagnose whether kidney disease is present in a given patient and at what stage. Conversely, KidneyIntelX is designed to predict whether or not an adult patient with type 2 diabetes and chronic kidney disease stages 1-3b will progress, possibly resulting in kidney failure.

In fact, KidneyIntelX has a growing body of evidence via validation, utility and economic studies, including a demonstrated 72% improvement in predicting those patients who are at high risk for rapid progressive decline in kidney function vs current standard of care.

Request a Meeting
Order Test
About Test
See Evidence
Indication for Use
Risk Information
Easy Implementation